Condition: Atrial Fibrillation · Stroke · Bleeding · Sponsor: Icahn School of Medicine at Mount Sinai
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.
This description comes directly from the study's public registry record.
Jonathan Hupf · (212) 659-6862 · Jonathan.Hupf@mountsinai.org
Always discuss trial participation with your own doctor first.
| CHI St. Vincent, Arkansas | Little Rock, Arkansas, United States | Recruiting |
| University of Southern California | Los Angeles, California, United States | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Stanford University | Stanford, California, United States | Recruiting |
| Medical Center of Aurora | Aurora, Colorado, United States | Active Not Recruiting |
| Western Connecticut Hospital Systems | Danbury, Connecticut, United States | Active Not Recruiting |
| Yale Medicine | New Haven, Connecticut, United States | Recruiting |
| MedStar Washington Hospital Center | Washington D.C., District of Columbia, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Piedmont Healthcare Inc. | Atlanta, Georgia, United States | Recruiting |
| Lutheran Medical Center | Fort Wayne, Indiana, United States | Active Not Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Active Not Recruiting |
+ 94 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04045665